Global Antisense and RNAi Therapeutics Drug Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antisense and RNAi Therapeutics Drug Market Insights, Forecast to 2034
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Market Analysis and InsightsGlobal Antisense and RNAi Therapeutics Drug Market
Global Antisense and RNAi Therapeutics Drug market is expected to reach to US$ 869 million in 2024, with a positive growth of %, compared with US$ 852 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Antisense and RNAi Therapeutics Drug industry is evaluated to reach US$ 1250.2 million in 2029. The CAGR will be 6.3% during 2024 to 2029.
Globally, Antisense and RNAi Therapeutics Drug key companies include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Antisense and RNAi Therapeutics Drug were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Antisense and RNAi Therapeutics Drug market and estimated to attract more attentions from industry insiders and investors.
Antisense and RNAi Therapeutics Drug can be divided into Antisense Oligonucleotide, Aptamer and Other,, etc. Antisense Oligonucleotide is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Antisense and RNAi Therapeutics Drug is widely used in various fields, such as Neuromuscular Diseases, ATTR, Hepatic VOD and Other, etc. Neuromuscular Diseases provides greatest supports to the Antisense and RNAi Therapeutics Drug industry development. In 2022, global % revenue of Antisense and RNAi Therapeutics Drug went into Neuromuscular Diseases filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Antisense and RNAi Therapeutics Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Antisense and RNAi Therapeutics Drug market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Antisense and RNAi Therapeutics Drug introduction, etc. Antisense and RNAi Therapeutics Drug Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports’s Conclusions of Antisense and RNAi Therapeutics Drug
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Antisense and RNAi Therapeutics Drug Market
Global Antisense and RNAi Therapeutics Drug market is expected to reach to US$ 869 million in 2024, with a positive growth of %, compared with US$ 852 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Antisense and RNAi Therapeutics Drug industry is evaluated to reach US$ 1250.2 million in 2029. The CAGR will be 6.3% during 2024 to 2029.
Globally, Antisense and RNAi Therapeutics Drug key companies include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Antisense and RNAi Therapeutics Drug were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Antisense and RNAi Therapeutics Drug market and estimated to attract more attentions from industry insiders and investors.
Antisense and RNAi Therapeutics Drug can be divided into Antisense Oligonucleotide, Aptamer and Other,, etc. Antisense Oligonucleotide is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Antisense and RNAi Therapeutics Drug is widely used in various fields, such as Neuromuscular Diseases, ATTR, Hepatic VOD and Other, etc. Neuromuscular Diseases provides greatest supports to the Antisense and RNAi Therapeutics Drug industry development. In 2022, global % revenue of Antisense and RNAi Therapeutics Drug went into Neuromuscular Diseases filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Antisense and RNAi Therapeutics Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Antisense and RNAi Therapeutics Drug market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Antisense and RNAi Therapeutics Drug introduction, etc. Antisense and RNAi Therapeutics Drug Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports’s Conclusions of Antisense and RNAi Therapeutics Drug
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices